| 1286 | Coronavirus Infections |
| 1282 | Humans |
| 1281 | Pneumonia, Viral |
| 1272 | Pandemics |
| 1093 | Betacoronavirus |
| 327 | Female |
| 295 | Male |
| 225 | Middle Aged |
| 219 | France |
| 210 | Aged |
| 164 | Adult |
| 92 | Antiviral Agents |
| 89 | Aged, 80 and over |
| 76 | Risk Factors |
| 73 | Retrospective Studies |
| 73 | Europe |
| 73 | Child |
| 71 | Practice Guidelines as Topic |
| 68 | Clinical Laboratory Techniques |
| 67 | Intensive Care Units |
| 66 | Coronavirus |
| 65 | Hydroxychloroquine |
| 61 | Infection Control |
| 61 | Animals |
| 59 | Adolescent |
| 57 | Disease Outbreaks |
| 56 | Young Adult |
| 56 | China |
| 55 | Severity of Illness Index |
| 52 | Treatment Outcome |
| 49 | Comorbidity |
| 48 | Quarantine |
| 47 | Hospitalization |
| 43 | Tomography, X-Ray Computed |
| 43 | Telemedicine |
| 42 | Neoplasms |
| 41 | Time Factors |
| 41 | Global Health |
| 40 | Respiratory Distress Syndrome, Adult |
| 38 | Societies, Medical |
| 38 | Risk Assessment |
| 37 | Respiration, Artificial |
| 37 | Peptidyl-Dipeptidase A |
| 36 | Prospective Studies |
| 36 | Pregnancy |
| 36 | Lung |
| 36 | Italy |
| 36 | Delivery of Health Care |
| 35 | SARS Virus |
| 35 | Infectious Disease Transmission, Patient-to-Professional |
| 35 | Critical Care |
| 34 | Age Factors |
| 33 | Child, Preschool |
| 32 | Disease Management |
| 32 | Azithromycin |
| 31 | Personal Protective Equipment |
| 31 | Critical Illness |
| 29 | Severe Acute Respiratory Syndrome |
| 29 | Infant |
| 29 | Health Personnel |
| 28 | United States |
| 28 | Surveys and Questionnaires |
| 27 | RNA, Viral |
| 27 | Prognosis |
| 27 | Communicable Disease Control |
| 26 | Infant, Newborn |
| 26 | Incidence |
| 25 | Triage |
| 25 | Public Health |
| 25 | Paris |
| 25 | Drug Therapy, Combination |
| 23 | Pregnancy Complications, Infectious |
| 23 | Olfaction Disorders |
| 23 | Emergencies |
| 23 | Cohort Studies |
| 22 | Pulmonary Embolism |
| 22 | Disease Progression |
| 22 | Anticoagulants |
| 21 | Prevalence |
| 21 | Medical Oncology |
| 20 | Spike Glycoprotein, Coronavirus |
| 20 | Sensitivity and Specificity |
| 20 | Reverse Transcriptase Polymerase Chain Reaction |
| 20 | Host-Pathogen Interactions |
| 20 | Cytokines |
| 20 | Clinical Trials as Topic |
| 20 | Chloroquine |
| 20 | Antibodies, Viral |
| 19 | Social Isolation |
| 19 | Inflammation |
| 19 | Consensus |
| 19 | Cardiovascular Diseases |
| 19 | Biomarkers |
| 18 | Virus Replication |
| 18 | Viral Load |
| 18 | Fibrin Fibrinogen Degradation Products |
| 17 | Travel |
| 17 | Thrombosis |
| 17 | Risk |
| 17 | Renin-Angiotensin System |
| 17 | Registries |
| 17 | Cytokine Release Syndrome |
| 16 | Viral Vaccines |
| 16 | Time-to-Treatment |
| 16 | Spain |
| 16 | Mental Disorders |
| 16 | Immunologic Factors |
| 16 | Health Services Accessibility |
| 16 | Genome, Viral |
| 16 | Disease Transmission, Infectious |
| 16 | Diagnosis, Differential |
| 16 | Biomedical Research |
| 16 | Anti-Bacterial Agents |
| 15 | Nasopharynx |
| 15 | Epidemics |
| 15 | Emergency Service, Hospital |
| 15 | Antibodies, Monoclonal, Humanized |
| 15 | Ambulatory Care |
| 14 | Randomized Controlled Trials as Topic |
| 14 | Radiography, Thoracic |
| 14 | Patient Selection |
| 14 | Obesity |
| 14 | Extracorporeal Membrane Oxygenation |
| 14 | Cross Infection |
| 13 | Vero Cells |
| 13 | Urology |
| 13 | Stroke |
| 13 | Real-Time Polymerase Chain Reaction |
| 13 | Population Surveillance |
| 13 | Patient Isolation |
| 13 | Immunity, Innate |
| 13 | Drug Repositioning |
| 13 | Cross-Sectional Studies |
| 13 | Chlorocebus aethiops |
| 13 | Acute Disease |
| 12 | Symptom Assessment |
| 12 | Patient Care Team |
| 12 | Operating Rooms |
| 12 | Models, Statistical |
| 12 | Masks |
| 12 | Magnetic Resonance Imaging |
| 12 | Influenza, Human |
| 12 | Immunocompromised Host |
| 12 | Elective Surgical Procedures |
| 12 | Coinfection |
| 12 | Algorithms |
| 12 | Alanine |
| 12 | Aerosols |
| 12 | Adrenal Cortex Hormones |
| 12 | Adenosine Monophosphate |
| 11 | Zoonoses |
| 11 | World Health Organization |
| 11 | Respiratory Insufficiency |
| 11 | Patient Safety |
| 11 | Otolaryngology |
| 11 | Internet |
| 11 | Infectious Disease Transmission, Vertical |
| 11 | Immunosuppressive Agents |
| 11 | Diabetes Mellitus |
| 11 | Clinical Decision-Making |
| 11 | Antimalarials |
| 10 | United Kingdom |
| 10 | Thrombophilia |
| 10 | Survival Rate |
| 10 | Practice Patterns, Physicians' |
| 10 | Pneumonia |
| 10 | Occupational Health |
| 10 | Lopinavir |
| 10 | Length of Stay |
| 10 | International Cooperation |
| 10 | Glucocorticoids |
| 10 | Drug Interactions |
| 10 | Disinfection |
| 10 | Digestive System Surgical Procedures |
| 10 | Case-Control Studies |
| 10 | Antineoplastic Agents |
| 10 | Angiotensin-Converting Enzyme Inhibitors |
| 10 | Amino Acid Sequence |
| 10 | Air Pollution |
| 9 | Withholding Treatment |
| 9 | Vulnerable Populations |
| 9 | Viral Nonstructural Proteins |
| 9 | Venous Thromboembolism |
| 9 | Tracheostomy |
| 9 | Survival Analysis |
| 9 | Stress, Psychological |
| 9 | Ritonavir |
| 9 | Prone Position |
| 9 | Preoperative Care |
| 9 | Polymerase Chain Reaction |
| 9 | Phylogeny |
| 9 | Patient Positioning |
| 9 | Occupational Diseases |
| 9 | Nursing Homes |
| 9 | Models, Biological |
| 9 | Mass Screening |
| 9 | Internationality |
| 9 | Hypertension |
| 9 | Hospitals, University |
| 9 | Hospital Units |
| 9 | Health Services Needs and Demand |
| 9 | Health Priorities |
| 9 | Follow-Up Studies |
| 9 | Equipment Design |
| 9 | Emergency Medical Services |
| 9 | Brain Ischemia |
| 9 | Anxiety |
| 8 | Virus Internalization |
| 8 | Ultrasonography |
| 8 | Research Design |
| 8 | Phenotype |
| 8 | Ophthalmology |
| 8 | Mortality |
| 8 | Models, Theoretical |
| 8 | Middle East Respiratory Syndrome Coronavirus |
| 8 | Mice |
| 8 | Mental Health |
| 8 | Mental Health Services |
| 8 | Lung Neoplasms |
| 8 | Intubation, Intratracheal |
| 8 | Information Dissemination |
| 8 | Infectious Disease Transmission, Professional-to-Patient |
| 8 | Immunoglobulin G |
| 8 | Hypoxia |
| 8 | Hypoglycemic Agents |
| 8 | Hygiene |
| 8 | Health Care Surveys |
| 8 | Disseminated Intravascular Coagulation |
| 8 | Continuity of Patient Care |
| 8 | Communicable Diseases, Emerging |
| 8 | Breast Neoplasms |
| 8 | Blood Coagulation |
| 8 | Blood Coagulation Disorders |
| 8 | Asthma |
| 8 | Anti-Inflammatory Agents |
| 8 | Africa |
| 8 | Adaptation, Psychological |
| 7 | Viral Proteins |
| 7 | Venous Thrombosis |
| 7 | Urologic Diseases |
| 7 | Suicide |
| 7 | Socioeconomic Factors |
| 7 | Sex Factors |
| 7 | Serologic Tests |
| 7 | Seasons |
| 7 | Renal Dialysis |
| 7 | Radiation Oncology |
| 7 | Protective Devices |
| 7 | Oxygen |
| 7 | Outcome Assessment, Health Care |
| 7 | Nervous System Diseases |
| 7 | Mutation |
| 7 | Molecular Targeted Therapy |
| 7 | Models, Molecular |
| 7 | Laparoscopy |
| 7 | Kidney Transplantation |
| 7 | Iran |
| 7 | Interleukin-6 |
| 7 | Interdisciplinary Communication |
| 7 | Inpatients |
| 7 | Inflammatory Bowel Diseases |
| 7 | Immunoglobulins, Intravenous |
| 7 | Health Resources |
| 7 | Health Care Rationing |
| 7 | Guidelines as Topic |
| 7 | Forecasting |
| 7 | Fear |
| 7 | Exercise |
| 7 | Evidence-Based Medicine |
| 7 | Drug Combinations |
| 7 | Decision Making |
| 7 | Contact Tracing |
| 7 | Computed Tomography Angiography |
| 7 | Communication |
| 7 | Cities |
| 7 | Chronic Disease |
| 7 | Antibodies, Neutralizing |
| 7 | Africa South of the Sahara |
| 6 | Urologic Surgical Procedures |
| 6 | Tuberculosis |
| 6 | Taste |
| 6 | Systemic Inflammatory Response Syndrome |
| 6 | Surgical Oncology |
| 6 | Surgeons |
| 6 | Stress Disorders, Post-Traumatic |
| 6 | Software |
| 6 | Smell |
| 6 | Skin Diseases |
| 6 | Receptors, Virus |
| 6 | Point-of-Care Testing |
| 6 | Pediatrics |
| 6 | Patient Admission |
| 6 | Oxygen Inhalation Therapy |
| 6 | Otorhinolaryngologic Surgical Procedures |
| 6 | Occupational Exposure |
| 6 | Mucocutaneous Lymph Node Syndrome |
| 6 | Lymphopenia |
| 6 | Lung Transplantation |
| 6 | Long QT Syndrome |
| 6 | Liver Transplantation |
| 6 | Immune System |
| 6 | Hospital Mortality |
| 6 | Heart Diseases |
| 6 | Health Policy |
| 6 | Health Behavior |
| 6 | Gynecologic Surgical Procedures |
| 6 | Genital Neoplasms, Female |
| 6 | Fatal Outcome |
| 6 | Electrocardiography |
| 6 | Echocardiography |
| 6 | Drug Synergism |
| 6 | Computer Simulation |
| 6 | Civil Defense |
| 6 | Brazil |
| 6 | Brain Diseases |
| 6 | Basic Reproduction Number |
| 6 | Attitude of Health Personnel |
| 5 | Virulence |
| 5 | Viral Tropism |
| 5 | Viral Envelope Proteins |
| 5 | Videoconferencing |
| 5 | Ventilation |
| 5 | Thromboembolism |
| 5 | Taste Disorders |
| 5 | Structure-Activity Relationship |
| 5 | Serine Endopeptidases |
| 5 | Risk Management |
| 5 | Republic of Korea |
| 5 | Psychotropic Drugs |
| 5 | Psychiatry |
| 5 | Protein Kinase Inhibitors |
| 5 | Procedures and Techniques Utilization |
| 5 | Pregnant Women |
| 5 | Predictive Value of Tests |
| 5 | Postoperative Complications |
| 5 | Pilot Projects |
| 5 | Patient Care Management |
| 5 | Patient Acceptance of Health Care |
| 5 | Particulate Matter |
| 5 | Palliative Care |
| 5 | Otorhinolaryngologic Diseases |
| 5 | Lung Diseases |
| 5 | Interferon Type I |
| 5 | Immunosuppression |
| 5 | Immunization, Passive |
| 5 | Hospitals |
| 5 | Hospital Bed Capacity |
| 5 | History, 21st Century |
| 5 | Hematopoietic Stem Cell Transplantation |
| 5 | Heart Failure |
| 5 | Healthcare Disparities |
| 5 | Head and Neck Neoplasms |
| 5 | Guideline Adherence |
| 5 | Germany |
| 5 | Feasibility Studies |
| 5 | Family |
| 5 | Evolution, Molecular |
| 5 | Electroencephalography |
| 5 | Early Diagnosis |
| 5 | Dyspnea |
| 5 | Dysgeusia |
| 5 | Drug Monitoring |
| 5 | Drug Evaluation, Preclinical |
| 5 | Drug Administration Schedule |
| 5 | Dose-Response Relationship, Drug |
| 5 | Disease Susceptibility |
| 5 | Diabetes Complications |
| 5 | Depression |
| 5 | Contraindications, Drug |
| 5 | Chiroptera |
| 5 | Chilblains |
| 5 | Cause of Death |
| 5 | CD8-Positive T-Lymphocytes |
| 5 | C-Reactive Protein |
| 5 | Blood Glucose |
| 5 | Blood Donors |
| 5 | Bed Conversion |
| 5 | Attitude to Health |
| 5 | Asymptomatic Infections |
| 5 | Asymptomatic Diseases |
| 5 | Anti-Inflammatory Agents, Non-Steroidal |
| 5 | Anemia, Sickle Cell |
| 5 | Air Microbiology |
| 5 | Aging |
| 5 | Age Distribution |
| 4 | Vitamin D |
| 4 | Visitors to Patients |
| 4 | Virus Attachment |
| 4 | Ventilators, Mechanical |
| 4 | Vaccination |
| 4 | Uterine Cervical Neoplasms |
| 4 | Urogenital Neoplasms |
| 4 | Universal Precautions |
| 4 | Treatment Failure |
| 4 | Transplant Recipients |
| 4 | Tertiary Care Centers |
| 4 | Surgical Procedures, Operative |
| 4 | Surgery Department, Hospital |
| 4 | Standard of Care |
| 4 | Specimen Handling |
| 4 | Social Distance |
| 4 | Sex Distribution |
| 4 | Seroepidemiologic Studies |
| 4 | Sequence Alignment |
| 4 | Sepsis |
| 4 | ST Elevation Myocardial Infarction |
| 4 | Rheumatic Diseases |
| 4 | Respiration |
| 4 | Resource Allocation |
| 4 | Reproducibility of Results |
| 4 | Referral and Consultation |
| 4 | RNA Replicase |
| 4 | Pulmonary Aspergillosis |
| 4 | Public Opinion |
| 4 | Psychotic Disorders |
| 4 | Proteomics |
| 4 | Protein Domains |
| 4 | Protein Binding |
| 4 | Professional Staff Committees |
| 4 | Professional Practice |
| 4 | Postoperative Care |
| 4 | Positron Emission Tomography Computed Tomography |
| 4 | Point-of-Care Systems |
| 4 | Pneumonia, Ventilator-Associated |
| 4 | Platelet Aggregation Inhibitors |
| 4 | Placenta |
| 4 | Patient Transfer |
| 4 | Patient Discharge |
| 4 | Oxidative Stress |
| 4 | Outpatients |
| 4 | Out-of-Hospital Cardiac Arrest |
| 4 | Organ Specificity |
| 4 | Ophthalmologists |
| 4 | Open Reading Frames |
| 4 | Nitric Oxide |
| 4 | Neutralization Tests |
| 4 | Needs Assessment |
| 4 | Myalgia |
| 4 | Multivariate Analysis |
| 4 | Molecular Dynamics Simulation |
| 4 | Molecular Docking Simulation |
| 4 | Long-Term Care |
| 4 | Logistic Models |
| 4 | Kidney Failure, Chronic |
| 4 | Intravitreal Injections |
| 4 | India |
| 4 | Immunotherapy |
| 4 | Immunoassay |
| 4 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| 4 | Host Microbial Interactions |
| 4 | Hospitals, Psychiatric |
| 4 | Hospital Administration |
| 4 | Homes for the Aged |
| 4 | Hemorrhage |
| 4 | HEK293 Cells |
| 4 | Guillain-Barre Syndrome |
| 4 | Geriatrics |
| 4 | Geriatric Assessment |
| 4 | Frail Elderly |
| 4 | Fluorodeoxyglucose F18 |
| 4 | Fibrinolytic Agents |
| 4 | Fever |
| 4 | Emergency Treatment |
| 4 | Drug Delivery Systems |
| 4 | Digestive System Diseases |
| 4 | Diabetes Mellitus, Type 2 |
| 4 | Diabetes Mellitus, Type 1 |
| 4 | Delirium |
| 4 | Databases, Factual |
| 4 | Data Collection |
| 4 | Data Accuracy |
| 4 | Cystic Fibrosis |
| 4 | Cyclosporine |
| 4 | Critical Pathways |
| 4 | Continuous Positive Airway Pressure |
| 4 | Containment of Biohazards |
| 4 | Combined Modality Therapy |
| 4 | Clozapine |
| 4 | Clinical Protocols |
| 4 | Climate |
| 4 | Cesarean Section |
| 4 | Cardiology |
| 4 | Carcinoma, Non-Small-Cell Lung |
| 4 | Canada |
| 4 | Brain |
| 4 | Blood Transfusion |
| 4 | Bayes Theorem |
| 4 | Autoimmune Diseases |
| 4 | Antirheumatic Agents |
| 4 | Angiotensin II Type 1 Receptor Blockers |
| 4 | Air Travel |
| 4 | Air Pollutants |
| 4 | Ageusia |
| 4 | Advisory Committees |
| 4 | Acute Kidney Injury |
| 4 | Activities of Daily Living |
| 3 | Virus Inactivation |
| 3 | Virology |
| 3 | Video Recording |
| 3 | Vasculitis |
